Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant Acinetobacter Baumannii grown in biofilms Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018
Inhaled colistin on Acinetobacter baumannii treatment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012
Synergistic activity of N-acetylcysteine and colistin against Stenotrophomonas maltophilia Source: International Congress 2017 – How can microbiology and translational research help physicians? Year: 2017
Potential treatment for nosocomial respiratory strains of extreme drug resistant acinetobacter baumanii Source: Eur Respir J 2007; 30: Suppl. 51, 410s Year: 2007
CusS-cusR mediate carbapenem-resistant Klebsiella pneumoniae resistant to tigecycline. Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019
In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012
Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Vancomycin MICs for respiratory isolates of community-associated MRSA and hospital-associated MRSA Source: Annual Congress 2007 - Pulmonary infections in the immunocompetent and immunocompromised host Year: 2007
Increasing global resistance to penicillin, macrolides and other antimicrobials among isolates of Streptococcus pneumoniae : susceptibility data from three years of the PROTEKT surveillance study Source: Eur Respir J 2003; 22: Suppl. 45, 486s Year: 2003
Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006
Resistance of Streptococcus pneumoniae to penicillin, azitromycin, ciprofloxacyn and ceftriaxon Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001
Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICUSource: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003
Staphlococcus aureus : susceptibility to antibacterial drugs and rate of MRSASource: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Emergence of penicillin resistant Streptococcus pneumoniae in Pakistan Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005
Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia Source: Eur Respir J 2007; 29: 548-560 Year: 2007
The resistance rates of Acinetobacter baumannii at endotracheal aspirate cultures Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012
Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016